Share

Delighted to announce that TRUEinvivo® has recently been awarded the medical CE Mark for our fast automated DOSEmapper Reader. This Class IIb medical device reads 300 micro silica bead thermoluminescent dosimeters (TLDs) in an hour without any manual interaction. Strings of characterised and calibrated bead TLDs are used to make DOSEmapper devices to enable clinicians to measure directly the actual radiotherapy doses (which are dozens of micro doses) that reach a target tumour. From the very first patient session, clinicians can compare those actual doses with the patient treatment plan and can make corrections for any system inaccuracies.

This facility gives clinicians early feedback and confidence about the overall treatment, it reduces side effects and their medical costs or re-treatment, and it gives patients a better experience and quality of life.
Related Posts
TrueInvivo's implant improves cancer treatment accuracy, accessible globally, supported by UKTI Sirius Programme.
TRUEinvivo joined SyndicateRoom investment platform in February 2019, leveraging its network to connect with potential investors, alongside Nexus Investment Ventures Ltd,
Dr. Shakardokht Jafari presents DOSEmapper™ at IPEM conference after ESTRO, highlighting glass beads' innovation in dosimetry.
USA patent granted for DOSEmapper™ TLD bead strings & Automated Reader.